drugset / Trial / NCT00053768

Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma

NCT00053768

RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different ways may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known which combination chemotherapy regimen followed by radiation therapy is more effective in treating aggressive non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying two combination chemotherapy regimens followed by radiation therapy to compare how well they work in treating patients with aggressive non-Hodgkin's lymphoma.

Timeline

Start
2002-04
Primary completion
2006-12-05
Completion
2006-12-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified 1400 mg/m2 Intravenous
Subject Doxorubicin Other / unclassified 32.5 mg/m2 Intravenous
Subject Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Subject Etoposide Small molecule 100 mg/m2 Intravenous
Subject Etoposide Small molecule 175 mg/m2 Intravenous
Subject Prednisone Other / unclassified 100 mg Oral
Subject Vincristine Small molecule 2 mg Intravenous
Subject filgrastim Protein / enzyme biologic Subcutaneous

Indications